Pacira Pharmaceuticals (PCRX) Stock Forecast & Price Target

Compare

382 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

PCRX Analyst Ratings

Moderate Buy

4 Buy

2 Hold

1 Sell

Based on 7 analysts giving stock ratings to

Pacira

Pharmaceuticals

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

PCRX Stock 12 Month Forecast

Average Price Target

$29.71

▲(44.93% Upside)

Based on 7 Wall Street analysts offering 12 month price targets for Pacira Pharmaceuticals in the last 3 months. The average price target is $29.71 with a high forecast of $38.00 and a low forecast of $23.00. The average price target represents a 44.93% change from the last price of $20.50.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"16":"$16","39":"$39","21.75":"$21.8","27.5":"$27.5","33.25":"$33.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":38,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$38.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":29.71,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$29.71</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":23,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$23.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[16,21.75,27.5,33.25,39],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2025","6":"Jun<br/>2025","9":"Oct<br/>2025","12":"Jan<br/>2026","25":"Jan<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,25.88,26.81230769230769,27.744615384615383,28.676923076923075,29.60923076923077,30.54153846153846,31.473846153846154,32.40615384615384,33.33846153846154,34.27076923076923,35.20307692307692,36.135384615384616,37.06769230769231,{"y":38,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,25.88,26.174615384615382,26.46923076923077,26.763846153846153,27.05846153846154,27.353076923076923,27.647692307692306,27.942307692307693,28.236923076923077,28.53153846153846,28.826153846153847,29.12076923076923,29.415384615384617,{"y":29.71,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,25.88,25.658461538461538,25.436923076923076,25.215384615384615,24.993846153846153,24.77230769230769,24.55076923076923,24.32923076923077,24.107692307692307,23.886153846153846,23.664615384615384,23.443076923076923,23.22153846153846,{"y":23,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":17.81,"date":1733011200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":18.84,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 23, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.33,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.05,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.07,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.75,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.24,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.25,"date":1751328000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":22.07,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.27,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 28, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.38,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 35, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.7,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 26, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.88,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$38.00

Average Price Target$29.71

Lowest Price Target$23.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Douglas Tsao

H.C. Wainwright

$38

Buy

85.37%

Upside

Reiterated

01/22/26

Analysts Are Bullish on These Healthcare Stocks: Pacira Pharmaceuticals (PCRX), Inspire Medical Systems (INSP)

Serge Belanger

Needham

$30

Buy

46.34%

Upside

Reiterated

01/09/26

Pacira: Maintaining Buy on Durable Non-Opioid Growth and Share Buybacks Despite Near-Term Revenue Softness

Les Sulewski

Truist Financial

$28

Buy

36.59%

Upside

Reiterated

01/09/26

Analysts Offer Insights on Healthcare Companies: Zymeworks (NASDAQ: ZYME), Pacira Pharmaceuticals (NASDAQ: PCRX) and Beta Bionics, Inc. (NASDAQ: BBNX)

Unknown Analyst

Jefferies

Not Ranked

Jefferies

$36

Buy

75.61%

Upside

Reiterated

01/09/26

Jefferies Remains a Buy on Pacira Pharmaceuticals (PCRX)

Jenna Davidner

Barclays

$27

Hold

31.71%

Upside

Initiated

12/08/25

Pacira initiated with an Equal Weight at BarclaysPacira initiated with an Equal Weight at Barclays

Hardik Parikh

J.P. Morgan

$23

Sell

12.20%

Upside

Reiterated

11/19/25

Pacira Pharmaceuticals Faces Revenue Decline Amid Generic Competition and Patent Challenges, Analyst Issues Sell Rating

Douglas Miehm

RBC Capital

$26

Hold

26.83%

Upside

Reiterated

11/07/25

Pacira Pharmaceuticals (PCRX) Receives a Hold from RBC Capital

Gary Nachman

Raymond James

Hold

―

Reiterated

10/06/25

Raymond James Sticks to Their Hold Rating for Pacira Pharmaceuticals (PCRX)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Douglas Tsao

H.C. Wainwright

$38

Buy

85.37%

Upside

Reiterated

01/22/26

Analysts Are Bullish on These Healthcare Stocks: Pacira Pharmaceuticals (PCRX), Inspire Medical Systems (INSP)

Serge Belanger

Needham

$30

Buy

46.34%

Upside

Reiterated

01/09/26

Pacira: Maintaining Buy on Durable Non-Opioid Growth and Share Buybacks Despite Near-Term Revenue Softness

Les Sulewski

Truist Financial

$28

Buy

36.59%

Upside

Reiterated

01/09/26

Analysts Offer Insights on Healthcare Companies: Zymeworks (NASDAQ: ZYME), Pacira Pharmaceuticals (NASDAQ: PCRX) and Beta Bionics, Inc. (NASDAQ: BBNX)

Unknown Analyst

Jefferies

Not Ranked

Jefferies

$36

Buy

75.61%

Upside

Reiterated

01/09/26

Jefferies Remains a Buy on Pacira Pharmaceuticals (PCRX)

Jenna Davidner

Barclays

$27

Hold

31.71%

Upside

Initiated

12/08/25

Pacira initiated with an Equal Weight at BarclaysPacira initiated with an Equal Weight at Barclays

Hardik Parikh

J.P. Morgan

$23

Sell

12.20%

Upside

Reiterated

11/19/25

Pacira Pharmaceuticals Faces Revenue Decline Amid Generic Competition and Patent Challenges, Analyst Issues Sell Rating

Douglas Miehm

RBC Capital

$26

Hold

26.83%

Upside

Reiterated

11/07/25

Pacira Pharmaceuticals (PCRX) Receives a Hold from RBC Capital

Gary Nachman

Raymond James

Hold

―

Reiterated

10/06/25

Raymond James Sticks to Their Hold Rating for Pacira Pharmaceuticals (PCRX)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Pacira Pharmaceuticals

3 Months

xxx

Success Rate

14/36 ratings generated profit

Average Return

-2.81%

reiterated a xxx

rating 19 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 38.89% of your transactions generating a profit, with an average return of -2.81% per trade.

1 Year

Les SulewskiTruist Financial

Success Rate

4/16 ratings generated profit

Average Return

-33.98%

reiterated a buy rating 19 days ago

Copying Les Sulewski's trades and holding each position for 1 Year would result in 25.00% of your transactions generating a profit, with an average return of -33.98% per trade.

2 Years

xxx

Success Rate

4/16 ratings generated profit

Average Return

-35.49%

reiterated a xxx

rating 19 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 25.00% of your transactions generating a profit, with an average return of -35.49% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

PCRX Analyst Recommendation Trends

Rating

Aug 25

Oct 25

Nov 25

Dec 25

Jan 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, PCRX has received 10 Buy Ratings, 19 Hold Ratings, and 1 Sell Ratings. PCRX average Analyst price target in the past 3 months is 29.71.

Each month's total comprises the sum of three months' worth of ratings.

PCRX Financial Forecast

PCRX Earnings Forecast

Next quarter’s earnings estimate for PCRX is $0.91 with a range of $0.81 to $0.99. The previous quarter’s EPS was $0.70. PCRX beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.25% of the time in the same period. In the last calendar year PCRX has Performed in-line its overall industry.

PCRX Sales Forecast

Next quarter’s sales forecast for PCRX is $200.34M with a range of $196.90M to $203.20M. The previous quarter’s sales results were $179.52M. PCRX beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 49.18% of the time in the same period. In the last calendar year PCRX has Performed in-line its overall industry.

PCRX Stock Forecast FAQ

What is PCRX’s average 12-month price target, according to analysts?

Based on analyst ratings, Pacira Pharmaceuticals’s 12-month average price target is 29.71.

What is PCRX’s upside potential, based on the analysts’ average price target?

Pacira Pharmaceuticals has 44.93% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is PCRX a Buy, Sell or Hold?

Pacira Pharmaceuticals has a consensus rating of Moderate Buy which is based on 4 buy ratings, 2 hold ratings and 1 sell ratings.

What is Pacira Pharmaceuticals’s price target?

The average price target for Pacira Pharmaceuticals is 29.71. This is based on 7 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $38.00 ,the lowest forecast is $23.00. The average price target represents 44.93% Increase from the current price of $20.5.

What do analysts say about Pacira Pharmaceuticals?

Pacira Pharmaceuticals’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 7 Wall Streets Analysts.

How can I buy shares of PCRX?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Pacira Pharmaceuticals (PCRX) Stock Forecast & Price Target

PCRX Analyst Ratings

PCRX Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Pacira Pharmaceuticals

PCRX Analyst Recommendation Trends

PCRX Financial Forecast

PCRX Earnings Forecast

PCRX Sales Forecast

PCRX Stock Forecast FAQ

Detailed List of Analyst Forecasts